Noteworthy ETF Outflows: OMFL, MCK, ETN, PGR
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2024
0mins
Source: NASDAQ.COM
Stock Performance Overview: OMFL's share price is currently at $55.71, close to its 52-week high of $55.80 and significantly above its low of $46.79.
ETFs Trading Dynamics: ETFs function like stocks but involve trading "units" that can be created or destroyed based on investor demand, affecting the underlying holdings of the ETF.
Analyst Views on MCK
Wall Street analysts forecast MCK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MCK is 942.83 USD with a low forecast of 880.00 USD and a high forecast of 1000.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
12 Buy
2 Hold
0 Sell
Strong Buy
Current: 817.050
Low
880.00
Averages
942.83
High
1000.00
Current: 817.050
Low
880.00
Averages
942.83
High
1000.00
About MCK
McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.








